NVCR

NovoCure Ltd. (NVCR) | Rumor.io

NovoCure

NVCR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,430

Bullish sentiment (50-day avg)94%

Price to earnings ratio-13

Market capitalization1.8B

Earnings per share-1.3

Dividend yield (TTM)—

Revenue (annual)655.4M

Net income (annual)-136.2M

Social

What share of all stock conversation is about NVCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 24

NVCR's Lunar2 trial may be streamlined from n=730 to n=450-500 patients, potentially reducing costs and improving enrollment velocity.
NVCR's Lunar1 trial showed a 63% hazard ratio when comparing [TTF+ Keytruda] vs Keytruda alone in 2L NSCLC, implying a 34-month median overall survival for TTF + Keytruda in 1L NSCLC.
NVCR's revenue grew 15.6% in Q2, driven by strong performance of its Tumor Treating Fields (TTFields) therapy for cancer, with 5,128 patients in treatment, and 18% growth in patient numbers.

Generated by AI

Sentiment

Of the messages about NVCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6.25	75.9% -3.62
Bearish	—	—	0% -6.25	24.1% +3.62

Bullish· Jul 23

NovoCure's Q2 earnings report exceeded expectations, with revenue of $183.6M beating consensus estimates of $172.4M, and EPS of $(0.13) significantly better than the estimated $(0.33).
The company's Optune Pax is gaining traction, with Q2Q growth showing improving execution and renewed investor confidence, and Optune Lua had 20% active patients growth too.
NovoCure's Optune Met is on track for Q4 approval, and the company's technical setup is worth monitoring, with a potential breakout and strong momentum that could bring renewed trader interest.

Bearish· Jun 18

$NVCR's Phase 3 TRIDENT trial failed to meet its primary endpoint, showing no survival benefit for early TTFields initiation in glioblastoma patients.
The stock's performance is heavily influenced by the trial's outcome, with a significant decline in share price following the announcement.
The company's inability to demonstrate a statistically significant overall survival benefit for early TTFields initiation raises concerns about the effectiveness of its treatment in glioblastoma patients.

Generated by AI

Topics

Of the messages about NVCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	60.87%	9.99%
Earnings	—	—	4.35%	11.73%
Analysts	—	—	34.78%	10.9%
Announcements	—	—	0%	55.79%
Macro	—	—	0%	10.75%
Controversies	—	—	0%	0.83%

Earnings· Feb 23

Novocure Limited (NVCR) reported Q4 2022 earnings with a loss of $0.36, missing the consensus estimate by $0.04.
The company's revenue of $128.43M was in-line with estimates, but net profit margin declined by 57.75% YoY.
Novocure's Q4 2022 earnings were impacted by a decline in sales, with a 0.53% YoY increase in sales and a 57.14% YoY decrease in EPS.

Analysts· Jun 7

Wedbush upgraded Novocure to Neutral from Underperform, with a lower price target of $46.
Analysts are mildly confident about Novocure, with a 70% buy consensus among 14 analysts.
Multiple analysts lowered their price targets for Novocure, including HC Wainwright to $85 and Piper Sandler to $62.

Announcements· Feb 12

The FDA has approved Novocure's Optune Pax for the treatment of locally advanced pancreatic cancer, with a Phase 3 trial showing a statistically significant improvement in overall survival and delayed pain progression.
The approval marks the first new treatment in decades for locally advanced pancreatic cancer, with Optune Pax providing a new treatment approach that targets the unique electrical properties of cancer cells.
Novocure's shares have gained significantly, with some analysts projecting $700-750M in revenue for 2026 and a potential market share of 40%, with revenue potential estimated at $3.11 billion.

Technical Analysis· Apr 30

NVCR has a significant increase in volume, suggesting buying pressure.
NVCR is above its previous support level, indicating a potential trend reversal.
NVCR's price is near a trendline, with a potential breakout or reversal possible.

Generated by AI

Community

Of the messages about NVCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	34.38%	44.12%
Newcomers	—	0%	65.63%	55.88%

Regulars· Jul 24

The regulars are discussing the potential for NovoCure to streamline its Lunar2 trial by switching to a single primary endpoint of overall survival (OS), which could reduce costs and improve enrollment velocity, but the exact numbers and timeline are unclear.
The Lunar2 trial is expected to show a similar hazard ratio (HR) to the Lunar1 trial, with a HR of 0.63 comparing TTF + Keytruda vs Keytruda alone in 2L NSCLC, which would imply a 34-month median overall survival (mOS) for TTF + Keytruda in the Lunar2 trial.
The company is expected to start making money as reimbursement catches up, with the 285 patients on treatment at the end of the quarter potentially generating $12 million in revenue per quarter, and the regulars are anticipating an increase in patients and revenue for the next quarter.

Newcomers· Jul 23

Newcomers are focused on Novocure's strong Q2 earnings, with revenue beating estimates by 16% YoY and EPS significantly better than expected.
The company's raised FY26 guidance, with revenue expectations now at $710M-$725M, has investors optimistic about the company's future prospects.
Novocure's growing patient treatments and rising revenue, supported by new regulatory clearances for its TTFields devices, are seen as key drivers of the company's operational momentum.

Generated by AI

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

6d agoYahoo Finance Singapore

NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change

7d agoYahoo Finance Singapore

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the company, founded more th

11d agoYahoo Finance

Novocure at Morgan Stanley conference: growth, discipline and expansion

15d agoInvesting.com

NovoCure at Wells Fargo healthcare conference: launch momentum builds

20d agoInvesting.com

Novocure Reports Patient Data Exposure in Cybersecurity Incident

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

22d agoYahoo Finance

Also Discussed

Investors talking about NVCR also mention

#	Name	Attention
1	Zai Lab Limited ADRZLAB	0%0
2	Guardant Health Inc.GH	0%-0.11
3	SWAV - ShockWave Medical, Inc.	——
4	Kura Oncology, Inc.KURA	0%+0
5	Avanos Medical Inc.AVNS	0%0
6	ClearPoint Neuro Inc.CLPT	0.03%+0.02
7	MRTX - Mirati Therapeutics, Inc.	——
8	iShares iBonds Dec 2045 Term Treasury ETFIBGB	0%0
9	State Street My2034 Corporate Bond ETFMYCN	0%0
10	Russell Investments Global Infrastructure ETFRIFR	0%0

NovoCure Ltd.

Healthcare
Medical Devices

NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division. Its current commercial portfolio includes Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with these therapies used alongside standard cancer treatments in approved markets. The company operates across the United States, Europe, Japan, Greater China, and other international regions, supporting patients through portable device-based treatment systems and related services. NovoCure Ltd. plays a specialized role in the cancer care market by offering a device-led treatment platform for difficult-to-treat solid tumors, combining medical technology, clinical support, and oncology-focused commercialization.

Website

Location

Neuhofstrasse 21

Baar, 6340

Switzerland

Social

What share of all stock conversation is about NVCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 24

NVCR's Lunar2 trial may be streamlined from n=730 to n=450-500 patients, potentially reducing costs and improving enrollment velocity.
NVCR's Lunar1 trial showed a 63% hazard ratio when comparing [TTF+ Keytruda] vs Keytruda alone in 2L NSCLC, implying a 34-month median overall survival for TTF + Keytruda in 1L NSCLC.
NVCR's revenue grew 15.6% in Q2, driven by strong performance of its Tumor Treating Fields (TTFields) therapy for cancer, with 5,128 patients in treatment, and 18% growth in patient numbers.

Generated by AI

Sentiment

Of the messages about NVCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6.25	75.9% -3.62
Bearish	—	—	0% -6.25	24.1% +3.62

Bullish· Jul 23

NovoCure's Q2 earnings report exceeded expectations, with revenue of $183.6M beating consensus estimates of $172.4M, and EPS of $(0.13) significantly better than the estimated $(0.33).
The company's Optune Pax is gaining traction, with Q2Q growth showing improving execution and renewed investor confidence, and Optune Lua had 20% active patients growth too.
NovoCure's Optune Met is on track for Q4 approval, and the company's technical setup is worth monitoring, with a potential breakout and strong momentum that could bring renewed trader interest.

Bearish· Jun 18

$NVCR's Phase 3 TRIDENT trial failed to meet its primary endpoint, showing no survival benefit for early TTFields initiation in glioblastoma patients.
The stock's performance is heavily influenced by the trial's outcome, with a significant decline in share price following the announcement.
The company's inability to demonstrate a statistically significant overall survival benefit for early TTFields initiation raises concerns about the effectiveness of its treatment in glioblastoma patients.

Generated by AI

Topics

Of the messages about NVCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	60.87%	9.99%
Earnings	—	—	4.35%	11.73%
Analysts	—	—	34.78%	10.9%
Announcements	—	—	0%	55.79%
Macro	—	—	0%	10.75%
Controversies	—	—	0%	0.83%

Earnings· Feb 23

Novocure Limited (NVCR) reported Q4 2022 earnings with a loss of $0.36, missing the consensus estimate by $0.04.
The company's revenue of $128.43M was in-line with estimates, but net profit margin declined by 57.75% YoY.
Novocure's Q4 2022 earnings were impacted by a decline in sales, with a 0.53% YoY increase in sales and a 57.14% YoY decrease in EPS.

Analysts· Jun 7

Wedbush upgraded Novocure to Neutral from Underperform, with a lower price target of $46.
Analysts are mildly confident about Novocure, with a 70% buy consensus among 14 analysts.
Multiple analysts lowered their price targets for Novocure, including HC Wainwright to $85 and Piper Sandler to $62.

Announcements· Feb 12

The FDA has approved Novocure's Optune Pax for the treatment of locally advanced pancreatic cancer, with a Phase 3 trial showing a statistically significant improvement in overall survival and delayed pain progression.
The approval marks the first new treatment in decades for locally advanced pancreatic cancer, with Optune Pax providing a new treatment approach that targets the unique electrical properties of cancer cells.
Novocure's shares have gained significantly, with some analysts projecting $700-750M in revenue for 2026 and a potential market share of 40%, with revenue potential estimated at $3.11 billion.

Technical Analysis· Apr 30

NVCR has a significant increase in volume, suggesting buying pressure.
NVCR is above its previous support level, indicating a potential trend reversal.
NVCR's price is near a trendline, with a potential breakout or reversal possible.

Generated by AI

Community

Of the messages about NVCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	34.38%	44.12%
Newcomers	—	0%	65.63%	55.88%

Regulars· Jul 24

The regulars are discussing the potential for NovoCure to streamline its Lunar2 trial by switching to a single primary endpoint of overall survival (OS), which could reduce costs and improve enrollment velocity, but the exact numbers and timeline are unclear.
The Lunar2 trial is expected to show a similar hazard ratio (HR) to the Lunar1 trial, with a HR of 0.63 comparing TTF + Keytruda vs Keytruda alone in 2L NSCLC, which would imply a 34-month median overall survival (mOS) for TTF + Keytruda in the Lunar2 trial.
The company is expected to start making money as reimbursement catches up, with the 285 patients on treatment at the end of the quarter potentially generating $12 million in revenue per quarter, and the regulars are anticipating an increase in patients and revenue for the next quarter.

Newcomers· Jul 23

Newcomers are focused on Novocure's strong Q2 earnings, with revenue beating estimates by 16% YoY and EPS significantly better than expected.
The company's raised FY26 guidance, with revenue expectations now at $710M-$725M, has investors optimistic about the company's future prospects.
Novocure's growing patient treatments and rising revenue, supported by new regulatory clearances for its TTFields devices, are seen as key drivers of the company's operational momentum.

Generated by AI

NovoCure

Social

Jul 24

Bullish· Jul 23

Bearish· Jun 18

Earnings· Feb 23

Analysts· Jun 7

Announcements· Feb 12

Technical Analysis· Apr 30

Regulars· Jul 24

Newcomers· Jul 23

NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall

NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

Novocure at Morgan Stanley conference: growth, discipline and expansion

NovoCure at Wells Fargo healthcare conference: launch momentum builds

Novocure Reports Patient Data Exposure in Cybersecurity Incident

Also Discussed

NovoCure Ltd.

Company Information

Location

NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall

NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

Novocure at Morgan Stanley conference: growth, discipline and expansion

NovoCure at Wells Fargo healthcare conference: launch momentum builds

Novocure Reports Patient Data Exposure in Cybersecurity Incident

Also Discussed

Social

Jul 24

Bullish· Jul 23

Bearish· Jun 18

Earnings· Feb 23

Analysts· Jun 7

Announcements· Feb 12

Technical Analysis· Apr 30

Regulars· Jul 24

Newcomers· Jul 23